Trifluperidol HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 328207

CAS#: 2062-77-3 (HCl)

Description: Trifluperidol, also known as Trifluperidol HCl and R-2498, is a dopamine D2-receptor antagonist used to treat schizophrenia.

Chemical Structure

img
Trifluperidol HCl
CAS# 2062-77-3 (HCl)
Instruction

Theoretical Analysis

MedKoo Cat#: 328207
Name: Trifluperidol HCl
CAS#: 2062-77-3 (HCl)
Chemical Formula: C22H24ClF4NO2
Exact Mass: 0.00
Molecular Weight: 445.883
Elemental Analysis: C, 59.26; H, 5.43; Cl, 7.95; F, 17.04; N, 3.14; O, 7.18

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 749-13-3 (free base)   2062-77-3 (HCl)    

Synonym: Trifluperidol; Trifluperidol hydrochloride; R-2498; R 2498; R2498

IUPAC/Chemical Name: 1-(4-fluorophenyl)-4-(4-hydroxy-4-(3-(trifluoromethyl)phenyl)piperidin-1-yl)butan-1-one hydrochloride

InChi Key: VYGQXRZAHIZHQV-UHFFFAOYSA-N

InChi Code: InChI=1S/C22H23F4NO2.ClH/c23-19-8-6-16(7-9-19)20(28)5-2-12-27-13-10-21(29,11-14-27)17-3-1-4-18(15-17)22(24,25)26;/h1,3-4,6-9,15,29H,2,5,10-14H2;1H

SMILES Code: O=C(C1=CC=C(F)C=C1)CCCN2CCC(C3=CC=CC(C(F)(F)F)=C3)(O)CC2.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info: Related CAS# 749-13-3 (Trifluperidol) 2062-77-3 (Trifluperidol Hydrochloride)

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 445.88 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Szenohradszky J, Gibiszer PK, Pórszász J Jr, Gács E. Effects of beta adrenergic blocking drugs and trifluperidol on intestinal motility and splanchnic nerve activity in cats. Acta Chir Hung. 1983;24(4):307-21. PubMed PMID: 6670434.

2: Fortes ZB. The effect of trifluperidol on the contractile response of guinea-pig taenia coli to acetylcholine, histamine, potassium and calcium. Gen Pharmacol. 1984;15(5):423-5. PubMed PMID: 6510679.

3: Kowalski J, Labuzek K, Herman ZS. Flupentixol and trifluperidol reduce interleukin-1 beta and interleukin-2 release by rat mixed glial and microglial cell cultures. Pol J Pharmacol. 2004 Sep-Oct;56(5):563-70. PubMed PMID: 15591644.

4: Kowalski J, Labuzek K, Herman ZS. Flupentixol and trifluperidol reduce secretion of tumor necrosis factor-alpha and nitric oxide by rat microglial cells. Neurochem Int. 2003 Jul;43(2):173-8. PubMed PMID: 12620286.

5: Coughenour LL, Cordon JJ. Characterization of haloperidol and trifluperidol as subtype-selective N-methyl-D-aspartate (NMDA) receptor antagonists using [3H]TCP and [3H]ifenprodil binding in rat brain membranes. J Pharmacol Exp Ther. 1997 Feb;280(2):584-92. PubMed PMID: 9023267.

6: Singh SP, Giridhar C, Avasthi A. Neuroleptic malignant syndrome with trifluperidol. Br J Psychiatry. 1989 Oct;155:561-3. PubMed PMID: 2611583.

7: Marcucci F, Airoldi L, Mussini E, Garattini S. Distribution of haloperidol and trifluperidol in brain and blood of rats. Chem Biol Interact. 1972 May;4(6):427-30. PubMed PMID: 5030587.

8: Lewi PJ, Heykants JJ, Janssen PA. On the distribution and metabolism of neuroleptic drugs. 3. Pharmacokinetics of trifluperidol. Arzneimittelforschung. 1970 Nov;20(11):1701-5. PubMed PMID: 5536974.

9: Janssen PA, Allewijn FT. The distribution of the butyrophenones haloperidol, trifluperidol, moperone, and clofluperol in rats, and its relationship with their neuroleptic activity. Arzneimittelforschung. 1969 Feb;19(2):199-208. PubMed PMID: 5818759.

10: BISHOP MP, GALLANT DM. TRIFLUPERIDOL IN "PARANOID" AND "NON-PARANOID" SCHIZOPHRENICS. Curr Ther Res Clin Exp. 1965 Feb;7:96-101. PubMed PMID: 14260091.